UncategorizedCharacter Biosciences named among Fierce 15 biotech firms of 2025 – Longevity.Technology Empower Meds / September 24, 2025
UncategorizedInBrain Pharma to present long-term DIVE-I data at MDS 2025 – Longevity.Technology Empower Meds / September 24, 2025
UncategorizedCerevance to present Phase 2 solengepras data at Parkinson’s congress – Longevity.Technology Empower Meds / September 24, 2025
UncategorizedRemedium signs multi-target gene therapy deal with Eli Lilly – Longevity.Technology Empower Meds / September 24, 2025
UncategorizedMBX Biosciences’ weekly canvuparatide meets primary endpoint in Phase 2 trial – Longevity.Technology Empower Meds / September 24, 2025
UncategorizedCryopreservation startup lands $58m to ‘pause biological time’ Empower Meds / September 23, 2025
UncategorizedFDA grants accelerated approval to Forzinity for Barth syndrome – Longevity.Technology Empower Meds / September 22, 2025
UncategorizedTelomir Pharmaceuticals reports new in vitro data on Telomir-1’s epigenetic activity – Longevity.Technology Empower Meds / September 22, 2025
UncategorizedLifespan Research Institute launches Public Longevity Group to build trust in longevity science – Longevity.Technology Empower Meds / September 22, 2025
